Our Services

We conduct research and analyses which will provide decision support in issues with clinical, economic, ethical or policy consequences. We develop your ideas and address your business challenges using the tools, technologies and models from medicine, economics and statistics.

  • Post Authorization Safety Studies (PASS)

  • Epidemiology and registry analyses

  • Environmental Economics

  • Disease impact studies|forecasts|scenario building

  • Budget Impact Analysis

  • Economic and societal impact analyses of business and policy

  • End-to-end project management of large-scale register based studies

Pharmacoepidemiology

Safeguarding Patients Through Unique Registry-Based Health Research

Pharmacoepidemiology is the study of drug uses and effects in well defined populations. In the Nordic countries we can retrieve information from both national patient registries on a individual patient level and from a number of quality registries and clinical databases, which have been built over the past decades. Registry studies are a cost and time effective alternative to prospective clinical investigations.  Health and socioeconomic register data, from birth to death, is available for the whole Nordic population of 26 million people.

Over the years ApEHR has conducted major registry studies covering Denmark, Sweden, Norway, Finland and UK covering both sensitive register data requirements and anonymized register data. We are currently responsible for projects based on data approved by the National Health Agency (Denmark), THL (Finland), Socialstyrelsen (Sweden), REK (Norway) and NHS IC and ONS (UK) involving Civil Registration Systems, National Patient Registers, Cancer Registers, Cause-of-Death Registers and Medicines and Prescriptions Registers. 
Our partners and associated partners are experienced with handling register data and well acquainted with the Data Security and Research Services of Statistic’s Denmark.

ApHER provides research focused on regulatory requirement from the FDA and the EMA. As ENCePP partner we participate in the development of methodological standards on the design and reporting of drug and medical device safety studies.

Real World Evidence

Understanding impact of disease for individuals and the society.

ApHER promotes sound and scientific use of health data to help policy makers evaluate the effectiveness of new drug and device interventions. We provide the research and documentation for products, to improve market access in the Nordic region.

ApHER has conducted several epidemiological studies describing patient populations and treatment patterns of existing therapies and those new to the market. The well described disease populations in national and clinical health registers are optimal for describing drug uptake and to stratify patient populations by received treatment.

Data from national health registers may be combined with digital health information obtained from health monitoring devices. ApHER is experienced in developing study designs giving insight to patient’s self management of disease.

ApHER develops and applies the PROM structure of specific disease and medications to monitor the results of a treatment in a defined population over time. These surveys may be used to systematically detect how a patient group experience the effect of a new treatment method after its introduction to the marked. 

PROM is short for Patient reported Outcome Measure. PROM is an umbrella term covering quality of life (QOL) measures, but also other outcomes measures where patients’ views are presented. PROM includes measures on symptoms of diseases, level of functioning, as well as health related QOL. Measures of ‘patient satisfaction’ with a given care can also be included in PROM.

Outcomes research is the study of treatment effect measured by outcomes other than those evaluated in clinical trials, in a non-interventional setting.

Health Economics

Making informed decisions in health care resource priorization

The pharmaceutical and medical device industry is globally facing increasing requirement to document the cost-effectiveness of their products.  ApHER is specialised in providing such documentation, through a unique approach using register-based health & socioeconomic data to build health economic models.

More than ever, building up evidence on health care system value of new and existing technologies is in demand. ApHER supports organisations in documenting the cost-effectiveness of their products. We collaborate with academic institutions to ensure a fair and transparent documentation of value.

  • Budget impact models
  • Pharmaceutical product and medical device cost-effectiveness studies

ApHER provides data driven strategic advice on priority setting in pharmaceutical product and medical device development. Through our collaboration with academic institutions and health care professionals we provide insight to health care system organisation and decision making.